Gland Pharma · NSE: GLAND · BSE: 543245
Q4 FY24 results · Jan–Mar 2024
Gland Pharma reported revenue from operations of ₹1,537.45 crore (up 95.9% from Q4 FY23) and net profit of ₹192.42 crore (up 144.6% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,537.45 | 785.01 | +95.9% | 1,545.15 | −0.5% |
| Other income | 42.15 | 38.94 | +8.2% | 37.39 | +12.7% |
| Total income | 1,579.60 | 823.95 | +91.7% | 1,582.55 | −0.2% |
| Profit before tax | 298.23 | 111.15 | +168.3% | 283.16 | +5.3% |
| Net profit for the period | 192.42 | 78.68 | +144.6% | 191.86 | +0.3% |
| EPS, basic (₹) | 11.68 | 4.78 | +144.4% | 11.65 | +0.3% |
| Net margin (%) | 12.5 | 10.0 | 12.4 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,174.83 | 785.42 | +49.6% | 1,097.86 | +7.0% |
| Other income | 46.95 | 38.94 | +20.6% | 43.39 | +8.2% |
| Total income | 1,221.79 | 824.36 | +48.2% | 1,141.25 | +7.1% |
| Profit before tax | 432.69 | 111.91 | +286.6% | 371.75 | +16.4% |
| Net profit for the period | 321.41 | 79.21 | +305.8% | 276.81 | +16.1% |
| EPS, basic (₹) | 19.51 | 4.81 | +305.6% | 16.81 | +16.1% |
| Net margin (%) | 27.4 | 10.1 | 25.2 |
Consolidated
- Filed with BSE
- 23 May 2024, 12:56 IST
- Board meeting
- 22 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 May 2024, 12:56 IST
- Board meeting
- 22 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE